E-commerce conglomerate Alibaba, along with its U.S.-based payment processor, AUS Merchant Services, have agreed to pay a combined sum of $600 million to settle allegations that they failed to prevent the sale and importation of illegal drugs, chemicals, and pharmaceutical counterfeiting equipment into the United States through their platforms between 2016 and 2024. The U.S. Justice Department announced the resolution on Wednesday, stating that both companies accepted responsibility for the actions of their employees and will enhance their compliance programs as part of non-prosecution agreements. The probe, which involved over 40 undercover purchases of illicit pharmaceuticals and counterfeiting equipment by law enforcement agencies, revealed that Alibaba's compliance measures were inadequate and failed to prevent approximately 80,000 product sales with a combined merchandise value exceeding $200 million. The U.S. government also asserted that the U.S.-based payment processor's anti-money laundering compliance program was insufficient, allowing some merchants to use its services for facilitating the sale and importation of banned products. This settlement underscores the U.S. Department of Justice's dedication to ensuring that e-commerce and digital payment platforms eradicate foreign pharmaceuticals deemed illegal, unapproved, misbranded, or dangerous from their marketplaces, as stated by Assistant U.S. Attorney General Brett Shumate. Alibaba operates some of the world's largest e-commerce platforms, including Alibaba.com and AliExpress.com.